[
  {
    "ts": "2025-12-25T08:10:05+00:00",
    "headline": "Should New Institutional Support and Analyst Optimism Around Farapulse Reshape Boston Scientific (BSX) Investors’ Thesis?",
    "summary": "In recent months, Parnassus Core Equity Fund disclosed a new position in Boston Scientific, while TD Cowen reiterated its positive stance and named the medical device maker its “Best Idea for 2026,” citing products such as Farapulse and Watchman as key growth engines. Together, this institutional backing and upbeat analyst commentary spotlight how Boston Scientific’s early lead in pulsed field ablation and structural heart devices is shaping expectations for its long-term earnings...",
    "url": "https://finance.yahoo.com/news/institutional-support-analyst-optimism-around-081005949.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ca5ead63-4d39-3cf0-b349-15354c8e2b02",
      "content": {
        "id": "ca5ead63-4d39-3cf0-b349-15354c8e2b02",
        "contentType": "STORY",
        "title": "Should New Institutional Support and Analyst Optimism Around Farapulse Reshape Boston Scientific (BSX) Investors’ Thesis?",
        "description": "",
        "summary": "In recent months, Parnassus Core Equity Fund disclosed a new position in Boston Scientific, while TD Cowen reiterated its positive stance and named the medical device maker its “Best Idea for 2026,” citing products such as Farapulse and Watchman as key growth engines. Together, this institutional backing and upbeat analyst commentary spotlight how Boston Scientific’s early lead in pulsed field ablation and structural heart devices is shaping expectations for its long-term earnings...",
        "pubDate": "2025-12-25T08:10:05Z",
        "displayTime": "2025-12-25T08:10:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFax.1EIpS7VVYvaDN0jRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OB69YGFZw788CGHTsahrkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/institutional-support-analyst-optimism-around-081005949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/institutional-support-analyst-optimism-around-081005949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-25T17:03:54+00:00",
    "headline": "What Analysts Think Is Changing In The Boston Scientific Growth Story",
    "summary": "Boston Scientific's latest narrative update reflects only a subtle recalibration, with the fair value estimate nudging from about $126.48 to $125.86 per share as revenue growth expectations edge higher and the discount rate shifts marginally lower. These small tweaks highlight an ongoing tug of war between bullish views that see durable double digit expansion and growing skepticism that much of that strength is already embedded in the stock. Read on to see how you can stay on top of these...",
    "url": "https://finance.yahoo.com/news/analysts-think-changing-boston-scientific-170354600.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e8e541c0-79f6-3c2a-909b-66dcf097d341",
      "content": {
        "id": "e8e541c0-79f6-3c2a-909b-66dcf097d341",
        "contentType": "STORY",
        "title": "What Analysts Think Is Changing In The Boston Scientific Growth Story",
        "description": "",
        "summary": "Boston Scientific's latest narrative update reflects only a subtle recalibration, with the fair value estimate nudging from about $126.48 to $125.86 per share as revenue growth expectations edge higher and the discount rate shifts marginally lower. These small tweaks highlight an ongoing tug of war between bullish views that see durable double digit expansion and growing skepticism that much of that strength is already embedded in the stock. Read on to see how you can stay on top of these...",
        "pubDate": "2025-12-25T17:03:54Z",
        "displayTime": "2025-12-25T17:03:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFax.1EIpS7VVYvaDN0jRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OB69YGFZw788CGHTsahrkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-changing-boston-scientific-170354600.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-changing-boston-scientific-170354600.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]